The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the united states: A review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg

International Journal of Women's Health

Volumn 2, Issue 1, 2010, Pages 235-239

  Krishnan, Sheila ^a   Kiley, Jessica ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Continuous regimen; Ethinyl estradiol; Extended cycle; Oral contraceptive

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; LOSEASONIQUE; ORAL CONTRACEPTIVE AGENT; PLACEBO; UNCLASSIFIED DRUG;

BREAKTHROUGH BLEEDING; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; HUMAN; LOW DRUG DOSE; MENORRHAGIA; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARMACODYNAMICS; REVIEW; RHINOPHARYNGITIS; SINUSITIS; SPOTTING; VAGINA BLEEDING; VEIN THROMBOSIS;

EID: 77955537636     PISSN: None     EISSN: 11791411     Source Type: Book Series    
DOI: None     Document Type: Review

References (22)

1. Dickey RP, Dorr CH II. Oral contraceptives: selection of the proper pill. Obstet Gynecol. 1969;33(2):273-287.
2. Gerstman BB, Gross TP, Kennedy DL, Bennett RC, Tomita DK, Stadel BV. Trends in the content and use of oral contraceptives in the United States, 1964-1988. Am J Public Health. 1991;81(1):90-96.
3. Piper JM, Kennedy DL. Oral contraceptives in the United States: trends in content and potency. Int J Epidemiol. 1987;16(2):215-221.
4. Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol. 1993;81(6):1034-1047.
5. Gallo MF, Nanda K, Grimes DA, Schulz KF. Twenty micrograms vs.20 microg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials. Contraception. 2005;71(3):162-169.
6. Kiley J, Hammond C. Combined oral contraceptives: a comprehensive review. Clin Obstet Gynecol. 2007;50(4):868-877.
7. Wright KP, Johnson JV. Evaluation of extended and continuous use oral contraceptives. Ther Clin Risk Manag. 2008;4(5):905-911.
8. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril. 1999;72(1):115-120.
9. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54(2):71-77.
10. Archer DF. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives. Contraception. 2006;74(5):359-366.
11. Andrist LC, Arias RD, Nucatola D, et al. Women's and providers' attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception. 2004;70(5):359-363.
12. Seasonale (levonorgestrel/ethinyl estradiol tablets). Current US Prescribing Information. Duramed Pharmaceuticals.
13. Anderson FD, Gibbons W, Portman D. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception. 2006;73(3):229-234.
14. Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception. 2006;74(6):439-445.
15. Jensen JT, Archer DF. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms. Expert Opin Pharmacother. 2008;9(2):319-327.
16. Speroff L, Darney PD. A Clinical Guide for Contraception. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
17. Teichmann A, Apter D, Emerich J, et al. Continuous, daily levonorgestrel/ethinyl estradiol vs 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial. Contraception. 2009;80(6):504-511.
18. LoSeasonique (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets). Current US Prescribing Information. Cincinnati, OH: Duramed Pharmaceuticals.
19. Kroll R, Reape KZ, Margolis M. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol. Contraception. 2010;81(1):41-48.
20. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003;68(2):89-96.
21. Edelman AB, Gallo MF, Jensen JT, Nichols MD, Schulz KF, Grimes DA. Continuous or extended cycle vs cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2005;(3):CD004695.
22. Kaunitz AM, Portman DJ, Hait H, Reape KZ. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive. Contraception. 2009;79(5):350-355.